Appeal 2007-3395
Application 10/260,733
immobilized on the array; (g) measuring the
amount of first and second fluorescent label on
each spot after the contacting of step (f) for each
serial dilution fraction and determining the
karyotype of each serial dilution fraction by
comparative genomic hybridization; (h)
contacting the sample of step (b) and serial dilution
fractions of the sample of step (d) with the array of
step (a) under conditions wherein the nucleic acid
in the samples can specifically hybridize to the
genomic nucleic acid segments on the array; (i)
measuring the amount of first and second
fluorescent label on each spot after the contacting
of step (h) for each serial dilution fraction and
determining the karyotype of each serial dilution
fraction by comparative genomic hybridization;
and, (j) selecting which dilution fraction
karyotype determination of step (g) most closely
determined the known karyotype, and selecting the
same serial dilution measurement in step (i) to
determine the karyotype of the sample of step (d),
thereby determining the degree of genetic
mosaicism in a cell population. [Specification at
4-5, ¶ 12.]
[12] The array-immobilized genome may comprise a normal genome or
karyotype, and the first sample may have a normal genome or
karyotype (Specification at 6-7, ¶ 21).
[13] The second sample may have a mosaic karyotype comprising two or
more cell subpopulations (Specification at 7, ¶ 22).
B. Bao
[14] Chromosomal abnormalities, which may or may not involve a change
in DNA sequence copy number from the normal one copy per
chromosome, are said to be involved in various human pathologies
(Bao at col. 1, ll. 24-32).
8
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013